HK Stock MarketDetailed Quotes

02235 MICROTECH MED-B

Watchlist

5.060
+0.260+5.42%

Market Closed Dec 13 16:08 CST

2.12BMarket Cap-13.46P/E (TTM)

MICROTECH MED-B Key Stats

Cash Flow

All

YOY

Hide blank lines

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(FY)Dec 31, 2020

(FY)Dec 31, 2019

Turnover

36.10%150.82M

45.86%253.23M

54.29%110.81M

14.66%173.61M

--71.82M

101.13%151.4M

45.15%75.28M

--51.86M

Operating income

36.10%150.82M

45.86%253.23M

54.29%110.81M

14.66%173.61M

71.82M

101.13%151.4M

45.15%75.28M

51.86M

Cost of sales

----

-107.89%-80.52M

-39.43%-38.73M

---27.78M

Operating expenses

-25.97%-67.02M

-39.08%-127.49M

-32.83%-53.2M

-13.85%-91.67M

-40.05M

-107.89%-80.52M

-39.43%-38.73M

-27.78M

Gross profit

45.45%83.8M

53.45%125.73M

81.32%57.61M

15.59%81.94M

31.77M

93.97%70.88M

51.74%36.54M

24.08M

Selling expenses

-50.20%-103.52M

-80.03%-210.09M

-76.72%-68.92M

-123.32%-116.7M

---39M

5.09%-52.26M

-103.90%-55.06M

---27M

Administrative expenses

12.68%-19.7M

-9.79%-45.6M

-57.54%-22.57M

-0.13%-41.53M

---14.32M

9.35%-41.48M

-36.12%-45.76M

---33.62M

Research and development expenses

-7.91%-34.55M

-14.75%-70.1M

-30.23%-32.02M

-69.29%-61.09M

---24.59M

56.00%-36.08M

-63.82%-82.01M

---50.06M

Profit from asset sales

----

---8.31K

----

Revaluation surplus

--140.41K

---15.62K

----

-Changes in the fair value of other assets

--140.41K

---15.62K

----

Impairment and provision

-55.77%-4.03M

8.72%-4.51M

-388.64%-2.58M

-302.24%-4.94M

---529K

-553.72%-1.23M

55.56%-188K

---423K

-Other impairment is provision

-55.77%-4.03M

8.72%-4.51M

-388.64%-2.58M

-302.24%-4.94M

---529K

-553.72%-1.23M

55.56%-188K

---423K

Special items of operating profit

595.41%6.76M

-53.19%10.59M

-34.77%971.96K

87.99%22.61M

--1.49M

-52.88%12.03M

192.92%25.53M

--8.72M

Operating profit

-6.80%-72.82M

-62.29%-195.31M

-49.23%-68.18M

-150.02%-120.35M

-45.69M

60.20%-48.14M

-54.45%-120.94M

-78.3M

Financing cost

-29.16%35.1M

-12.14%75.04M

31.06%49.55M

502,458.72%85.4M

--37.81M

94.48%-17K

0.96%-308K

---311K

Special items of earning before tax

-2.01%-33.81K

-4,796.74%-4.58M

47.39%-33.14K

---93.53K

---63K

----

Earning before tax

-102.27%-37.75M

-256.30%-124.85M

-134.97%-18.66M

27.23%-35.04M

-7.94M

60.29%-48.15M

-54.23%-121.25M

-78.61M

Tax

--11.74K

-10,755.18%-163.62K

----

---1.51K

----

After-tax profit from continuing operations

-102.21%-37.74M

-256.75%-125.02M

-134.97%-18.66M

27.23%-35.04M

-7.94M

60.29%-48.15M

-54.23%-121.25M

-78.61M

Earning after tax

-102.21%-37.74M

-256.75%-125.02M

-134.97%-18.66M

27.23%-35.04M

-7.94M

60.29%-48.15M

-54.23%-121.25M

-78.61M

Minority profit

----

---241K

----

Profit attributable to shareholders

-102.21%-37.74M

-256.75%-125.02M

-134.97%-18.66M

27.23%-35.04M

-7.94M

60.21%-48.15M

-53.93%-121.01M

-78.61M

Basic earnings per share

-125.00%-0.09

-262.50%-0.29

-100.00%-0.04

38.46%-0.08

-0.02

66.67%-0.13

-39.29%-0.39

-0.28

Diluted earnings per share

-125.00%-0.09

-262.50%-0.29

-100.00%-0.04

38.46%-0.08

-0.02

66.67%-0.13

-39.29%-0.39

-0.28

Currency Unit

CNY

Accounting Standards

CAS (2007)

HKAS

Audit Opinions

Unqualified Opinion

Auditor

Tianjian Certified Public Accountants (Special General Partnership)

Ernst & Young

	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(FY)Dec 31, 2020	(FY)Dec 31, 2019
Turnover	36.10%150.82M	45.86%253.23M	54.29%110.81M	14.66%173.61M	--71.82M	101.13%151.4M	45.15%75.28M	--51.86M
Operating income	36.10%150.82M	45.86%253.23M	54.29%110.81M	14.66%173.61M	71.82M	101.13%151.4M	45.15%75.28M	51.86M
Cost of sales	----	----	----	----	----	-107.89%-80.52M	-39.43%-38.73M	---27.78M
Operating expenses	-25.97%-67.02M	-39.08%-127.49M	-32.83%-53.2M	-13.85%-91.67M	-40.05M	-107.89%-80.52M	-39.43%-38.73M	-27.78M
Gross profit	45.45%83.8M	53.45%125.73M	81.32%57.61M	15.59%81.94M	31.77M	93.97%70.88M	51.74%36.54M	24.08M
Selling expenses	-50.20%-103.52M	-80.03%-210.09M	-76.72%-68.92M	-123.32%-116.7M	---39M	5.09%-52.26M	-103.90%-55.06M	---27M
Administrative expenses	12.68%-19.7M	-9.79%-45.6M	-57.54%-22.57M	-0.13%-41.53M	---14.32M	9.35%-41.48M	-36.12%-45.76M	---33.62M
Research and development expenses	-7.91%-34.55M	-14.75%-70.1M	-30.23%-32.02M	-69.29%-61.09M	---24.59M	56.00%-36.08M	-63.82%-82.01M	---50.06M
Profit from asset sales	----	----	----	---8.31K	----	----	----	----
Revaluation surplus	--140.41K	---15.62K	----	----	----	----	----	----
-Changes in the fair value of other assets	--140.41K	---15.62K	----	----	----	----	----	----
Impairment and provision	-55.77%-4.03M	8.72%-4.51M	-388.64%-2.58M	-302.24%-4.94M	---529K	-553.72%-1.23M	55.56%-188K	---423K
-Other impairment is provision	-55.77%-4.03M	8.72%-4.51M	-388.64%-2.58M	-302.24%-4.94M	---529K	-553.72%-1.23M	55.56%-188K	---423K
Special items of operating profit	595.41%6.76M	-53.19%10.59M	-34.77%971.96K	87.99%22.61M	--1.49M	-52.88%12.03M	192.92%25.53M	--8.72M
Operating profit	-6.80%-72.82M	-62.29%-195.31M	-49.23%-68.18M	-150.02%-120.35M	-45.69M	60.20%-48.14M	-54.45%-120.94M	-78.3M
Financing cost	-29.16%35.1M	-12.14%75.04M	31.06%49.55M	502,458.72%85.4M	--37.81M	94.48%-17K	0.96%-308K	---311K
Special items of earning before tax	-2.01%-33.81K	-4,796.74%-4.58M	47.39%-33.14K	---93.53K	---63K	----	----	----
Earning before tax	-102.27%-37.75M	-256.30%-124.85M	-134.97%-18.66M	27.23%-35.04M	-7.94M	60.29%-48.15M	-54.23%-121.25M	-78.61M
Tax	--11.74K	-10,755.18%-163.62K	----	---1.51K	----	----	----	----
After-tax profit from continuing operations	-102.21%-37.74M	-256.75%-125.02M	-134.97%-18.66M	27.23%-35.04M	-7.94M	60.29%-48.15M	-54.23%-121.25M	-78.61M
Earning after tax	-102.21%-37.74M	-256.75%-125.02M	-134.97%-18.66M	27.23%-35.04M	-7.94M	60.29%-48.15M	-54.23%-121.25M	-78.61M
Minority profit	----	----	----	----	----	----	---241K	----
Profit attributable to shareholders	-102.21%-37.74M	-256.75%-125.02M	-134.97%-18.66M	27.23%-35.04M	-7.94M	60.21%-48.15M	-53.93%-121.01M	-78.61M
Basic earnings per share	-125.00%-0.09	-262.50%-0.29	-100.00%-0.04	38.46%-0.08	-0.02	66.67%-0.13	-39.29%-0.39	-0.28
Diluted earnings per share	-125.00%-0.09	-262.50%-0.29	-100.00%-0.04	38.46%-0.08	-0.02	66.67%-0.13	-39.29%-0.39	-0.28
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	HKAS	HKAS	HKAS
Audit Opinions	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	Unqualified Opinion	Unqualified Opinion
Auditor	--	Tianjian Certified Public Accountants (Special General Partnership)	--	Ernst & Young	--	Ernst & Young	Ernst & Young	Ernst & Young

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List

Overall

No Data

Investment Theme

Pharmaceutical Companies

Intraday-2.21%

02235 MICROTECH MED-B

MICROTECH MED-B Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow